Drug resistance remains a central barrier to durable responses across cancer therapies, spanning targeted agents, cytotoxic chemotherapy, endocrine ...
A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results